

See what really matters Airway Inflammation

The New NIOX MINO[®]



Exhaled Nitric Oxide Point of Care Asthma Monitoring

A NEW DIMENSION IN ASTHMA CARE



www.micro-direct.com

Micro Direct, Inc. • 803 Webster Street • Lewiston, ME 04240 • (800) 588-3381

NIOX MINO® - The Asthma Inflammation Monitor for exhaled Nitric Oxide (eNO)

Asthma is defined as a chronic inflammatory process, which leads to airflow limitation and increased responsiveness to asthma triggers. Until now, routine assessment of the level of inflammation has not been possible.

Controlling the inflammation, rather than its consequences, can dramatically improve the treatment and care of your asthma patients.

Relying on the patient's history, subjective evaluation of current symptoms and lung function test results is considered reactive symptom control.

Be proactive - measure what really matters - exhaled Nitric Oxide (eNO) for inflammation status. This means that you can detect a deterioration in the patient's asthma before it causes problems.

NIOX MINO® - allows personalized asthma care

Inflammation measurement with NIOX MINO offers personalized asthma care that can dramatically improve the treatment and care of your patients.

It takes less than two minutes to get an eNO value of the inflammation. With results in hand, you and your patient get immediate feedback on the inflammatory status. The patient's understanding of the disease improves, which results in better adherence to treatment.

The NIOX® Value - the new Gold Standard in Inflammation Monitoring

The value you get from NIOX MINO, the NIOX Value, is always quality assured. Various factors can influence the measurement of the patient's inflammation. An accurate and reliable eNO value is vitally important for both the physician and the patient.

The NIOX Value together with other diagnostic parameters is the basis for important decisions concerning the patient's asthma management program.

NIOX MINO has a built-in, highly sensitive quality assurance system that will always guarantee an exact and accurate measurement that can be relied upon - The NIOX Value.

- Both low and high NIOX Values are of clinical significance ¹
- It's a predictor of steroid response ¹⁻⁷
- It improves the patient's understanding and improves adherence to treatment ^{8,9}
- It is cost effective ^{10,11}
- It optimizes dose adjustments ^{12,13}
- It predicts asthma relapse ¹⁴

Features

- Accurate results
- Disposable filters prevent contamination
- Touch-screen for quick, easy navigation
- Built-in flow regulator to assist in patient's flow rate control
- Quality assured
- Requires no calibration or maintenance
- Suitable for adults and children from seven years
- Demo mode shows procedure to give patient a better understanding of how to perform the test
- Data storage - test cards available for convenient patient data storage
- Data Manager PC software available for storage, printing and trending of test results
- Meets all ATS/ERS 2005 recommendations
- 510 (k) cleared by FDA
- Third party reimbursable using CPT code 95015



References

1. Hewitt RS, et al. Supporting the diagnosis of non-specific respiratory symptoms in primary care: the role of exhaled nitric oxide measurement and spirometry. *Prim Care Respir J.* 2008;17(2):97-103.
2. Smith AD, et al. Exhaled nitric oxide: a predictor of steroid response. *Am J Respir Crit Care Med.* 2005;172:453-9.
3. Zeiger, RS, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. *J Allergy Clin Immunol.* 2006;117(1):45-52.
4. Sorkness, CA, et al. Long-term comparison of 3 controller for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. *J Allergy Clin Immunol.* 2007;119(1):64-72.
5. Szefer, SJ, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. *J Allergy Clin Immunol.* 2002;109(3):410-8.
6. Little, SA, et al. Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma. *Thorax* 2000;55(3):232-4.
7. Knuffman, et al. Phenotypic predictors of long-term response to inhaled corticosteroid modifier therapies in pediatric asthma. *J Allergy Clin Immunol.* 2009;123(2):411-6.
8. Beck-Ripp J, et al. Changes of exhaled nitric oxide during steroid treatment of childhood asthma. *Eur Respir J.* 2002;19:1015-9.
9. Delgado-Corcoran C, et al. Exhaled nitric oxide reflects asthma severity and asthma control. *Pediatr Crit Care Med.* 2004;5(1):48-52.
10. Berg J, Lindgren P. Economic evaluation of FeNO measurement in diagnosis and 1-year management of asthma in Germany. *Respir Med.* 2008;102(2):219-31.
11. Price D, et al. An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom. *Allergy* 2009;Mar;64(3):431-8.
12. Smith AD, et al. Use of Exhaled Nitric Oxide Measurements to Guide Treatment in Chronic Asthma. *N Engl J Med.* 2005;352:2163-73.
13. Pijnenburg MW, et al. Titrating steroids on exhaled nitric oxide in asthmatic children: a randomized controlled trial. *Am J Respir Crit Care Med.* 2005;172:831-6.
14. Pijnenburg MW, et al. Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission. *Thorax* 2005;60:215-8.